A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice

Autoimmunity

Volumn 46, Issue 7, 2013, Pages 419-428

  Zhu, Fu Gang ^a   Jiang, Weiwen ^a   Bhagat, Lakshmi ^a   Wang, Daqing ^a   Yu, Dong ^a   Tang, Jimmy X ^a   Kandimalla, Ekambar R ^a   La Monica, Nicola ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

Antagonist; Anti DNA antibodies; Anti RNA antibodies; Oligodeoxynucleotide; Systemic lupus erythematosus; Toll like receptors

Indexed keywords

AUTOANTIBODY; CATALASE; CRYOPYRIN; DNA; FAS LIGAND; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTATHIONE PEROXIDASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; RIBONUCLEOPROTEIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; INFLAMMATION; KIDNEY; KIDNEY FUNCTION; MOUSE; NONHUMAN; PROTEINURIA; SPLEEN; SYSTEMIC LUPUS ERYTHEMATOSUS; UREA NITROGEN BLOOD LEVEL;

ANIMALS; AUTOANTIBODIES; DEOXYRIBONUCLEOTIDES; DOWN-REGULATION; FEMALE; INFLAMMATION MEDIATORS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED NZB; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTOR 9;

EID: 84885464688     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2013.798651     Document Type: Article

References (63)

1. Lawrence, R. C., C. G. Helmick, F. C. Arnett, R. A. Deyo, D. T. Felson, E. H. Giannini, et al. 1998. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41: 778-779.
2. Chakravarty, E. F., T. M. Bush, S. Manzi, A. E. Clarke, and M. M. Ward. 2007. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 56: 2092-2094. (Pubitemid 47110409)
3. Pons-Estel, G. J., G. S. Alarcón, L. Scofield, L. Reinlib, and G. S. Cooper. 2010. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 39: 257-268.
4. Tsokos, G. C. 2011. Systemic Lupus Erythematosus. New Engl J Med. 365: 2110-2121.
5. Lo, M. S., and G. C. Tsokos. 2012. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann NY Acad Sci. 1247: 138-152.
6. Dennis, G. J. 2012. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Clin Pharmacol Ther. 91: 143-149.
7. Chugh, P. K. 2012. Lupus: novel therapies in clinical development. Eur J Intern Med. 23: 212-218.
8. Postal, M., L. T. Costallat, and S. Appenzeller. 2012. Biological therapy in systemic lupus erythematosus. Int J Rheumatol. 2012: 578-641.
9. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 11: 373-384.
10. Reeves, W. H., S. Narain, and M. Satho. 2005. Autoantibodies in systemic lupus erythematosus. In Arthritis and Allied Conditions: A Textbook of Rheumatology, 15th ed. W. J. Koopman and L. W. Moreland, eds. Lippincot Williams & Wilkins, Philadelphia. p. 1497-1521.
11. Avalos, A. M., L. Busconi, and A. Marshak-Rothstein. 2012. Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity. 43: 76-83.
12. Avalos, A. M., K. Kiefer, J. Tian, S. Christensen, M. Shlomchik, A. J. Coyle, and A. Marshak-Rothstein. 2012. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity. 43: 103-110.
13. Teichmann, L. L., M. L. Ols, M. Kashgarian, B. Reizis, D. H. Kaplan, and M. J. Shlomchik. 2010. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity. 33: 967-978.
14. Means, T. K., E. Latz, F. Hayashi, M. R. Murali, D. T. Golenbock, and A. D. Luster. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 115: 407-417. (Pubitemid 40385482)
15. Marshak-Rothstein, A. 2006. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 6: 823-835. (Pubitemid 44631651)
16. Finke, D., M. L. Eloranta, and L. Rönnblom. 2010. Endogenous type I interferon inducers in autoimmune diseases. Autoimmunity. 42: 349-352.
17. Obermoser, G., and V. Pascual. 2010. The interferon-a signature of systemic lupus erythematosus. Lupus. 19: 1012-1019.
18. Rönnblom, L., G. M. Alm, and M. L. Eloranta. 2011. The type I IFN system in the development of lupus. Semin Immunol. 23: 113-121.
19. Sozzani, S., D. Bosisio, M. Scarsi, and A. Tincani. 2010. Type I interferons in systemic autoimmunity. Autoimmunity 43: 196-203.
20. Christensen, S. R., J. Shupe, K. Nickerson, M. Kashgarian, R. A. Flavell, and M. J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417-428. (Pubitemid 44354217)
21. Nickerson, K. M., S. R. Christensen, J. Shupe, M. Kashgarian, D. Kim, K. Elkon, and M. J. Shlomchik. 2010. TLR9 regulates TLR7-and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol. 184: 1840-1848.
22. Demaria, O., P. P. Pagni, S. Traub., A. de Gassart, N. Branzk, A. J. Murphy, D. M. Valenzuela, G. D. Yancopoulos, R. A. Flavell, and L. Alexopouloual. 2010. TLR8 deficiency leads to autoimmunity in mice. J Clin Invest. 120: 3651-3662.
23. Fox, R. 1996. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 5 Suppl. 1: S4-10.
24. Kuznik, A., M. Bencina, U. Svajger, M. Jeras, B. Rozman, and R. Jerala. 2011. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 186: 4794-4804.
25. Krieg, A. M., T. Wu, R. Weeratna, S. M. Efler, L. Love-Homan, L. Yang, A. K. Yi, D. Short, and H. L. Davis. 1998. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA. 95: 12631-12636. (Pubitemid 28483816)
26. Pisetsky, D. S., and C. F. Reich. 2000. Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. Clin Immunol. 96: 198-204.
27. Gursel, I., M. Gursel, H. Yamada, K. J. Ishii, F. Takeshita, and D. M. Klinman. 2003. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 171: 1393-1400. (Pubitemid 36900072)
28. Ashman, R. F., J. A. Goeken, E. Latz, and P. Lenert. 2011. Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding. Int Immunol. 23: 203-214.
29. Lenert, P. S. 2010. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm. 2010: 986596.
30. Barrat, F. J., T. Meeker, J. Gregorio, J. H. Chan, S. Uematsu, S. Akira, B., Chang, O. Duramad, and R. L. Coffman. 2005. Nucleic acids of mammalian origin can act as endogenous ligands for the Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 202: 1131-1139. (Pubitemid 41464506)
31. Barrat, F. J., T. Meeker, J. H. Chan, C. Guiducci, and R. L. Coffman. 2007. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol. 37: 3582-3586.
32. Dong, L., S. Ito, K. J. Ishii, and D. M. Klinman. 2005. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB NZW mice. Arthritis Rheum. 52: 651-658. (Pubitemid 40216332)
33. Patole, P.S., D. Zecher, R. D. Pawar, H-J. Grone, D. Schlondorff, and H.-J. Anders. 2005. G-Rich DNA suppresses systemic lupus. J Am Soc Nephrol. 16: 3273-3280. (Pubitemid 46187549)
34. Lenert, P., K. Yasuda, L. Busconi, P. Nelson, C. Fleenor, R. S. Ratnabalasuriar, P. L. Nagy, et al. 2009. Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA-and/or RNA-like analogues for treating lupus. Arthritis Res Ther. 11: R79.
35. Pawar, R. D., A. Ramanjaneyulu, O. P. Kulkarni, M. Lech, S. Segerer, and H.-J. Anders. 2007. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol. 18: 1721-1731. (Pubitemid 46870309)
36. Graham, K. L., L. Y. Lee, J. P. Higgins, L. Steinman, P. J. Utz, and P. P. Ho. 2010. Treatment with a Toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice. Autoimmunity. 43: 140-155.
37. Guiducci, C., M. Gong, Z. Xu, M. Gill, D. Chaussabel, T. Meeker, J. H. Chan, et al. 2010. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465: 937-941.
38. Agrawal, S., P. L. Iadorola, J. Temsamani, Q. Zhao, and D. Shaw. 1996. Effect of G-rich sequences on the synthesis, purification, hybridization, cell uptake, and hemolytic activity of oligonucleotides. Bioorg Med Chem Lett. 6: 2219-2214.
39. Agrawal, S., W. Tan, Q. Cai, X. Xie, and R. Zhang. 1997. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev 7: 245-249. (Pubitemid 27323088)
40. Lenert, P., L. Stunz, A.K. Yi, A. M. Krieg, and R. F. Ashman. 2001. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucl Acid Drug Dev. 11: 247-256. (Pubitemid 32852883)
41. Shirota, H., M. Gursel, and D. M. Klinman. 2004. Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFNg-and IL-12-mediated signaling. J Immunol. 173: 5002-5007. (Pubitemid 39402951)
42. Wang, D., L. Bhagat, D. Yu, F. G. Zhu, J. X. Tang, E. R. Kandimalla, and S. Agrawal. 2009. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J Med Chem. 52: 551-558.
43. Yu, D., D. Wang, F. G. Zhu, L. Bhagat, M. Dai, E. R. Kandimalla, and S. Agrawal. 2009. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of Toll-like receptors 7 and 9. J Med Chem. 52: 5108-5114.
44. Kandimalla, E. R., L. Bhagat, D. Wang, D. Yu, T. Sullivan, N. La Monica, and S. Agrawal. 2013. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 41: 3947-3961.
45. Jiang, W., F. G. Zhu, L. Bhagat, D. Yu, J. X. Tang, E. R. Kandimalla, N. La Monica, and S. Agrawal. 2013. A Tolllike Receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasomes activation in a model of IL-23-induced psoriasis. J Invest Dermatol. (in press). doi:10.1038/jid.2013.57.
46. Lambert, P. H., and F. J. Dixon. 1968. Pathogenesis of glomerulonephritis of NZB/W mice. J Exp Med. 127: 507-513.
47. Theofilopoulos, A. N., and F. J. Dixon. 1985. Murine models of SLE. Adv Immunol. 37: 269-285.
48. Leadbetter, E. A., I. R. Rifkin, A. M. Hohlbaum, B. C. Beaudette, M. J. Shlomchik, and A., Marshak-Rothstein. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Tolllike receptors. Nature 416: 603-607. (Pubitemid 34406754)
49. Rönnblom, L., and V. Pascual. 2008. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 17: 394-399. (Pubitemid 351798715)
50. Lin, L. C., Y. C. Chen, C. C. Chou, K. H. Hsieh, and B. L. Chiang. 1995. Dysregulation of T helper cell cytokines in autoimmune prone NZB x NZW F1 mice. Scand J Immunol. 42: 466-472.
51. Llorente, L., and Y. Richaud-Patin. 2003. The role of interleukin-10 in systemic lupus erythematosus. J Autoimmun. 20: 287-289. (Pubitemid 36677520)
52. Yin, Z., G. Bahtiyar, N. Zhang, L. Liu, P. Zhu, M. E. Robert, J. McNiff, M. P. Madaio, and J. Craft. 2002. IL-10 regulates murine lupus. J Immunol. 169: 2148-2155. (Pubitemid 34857682)
53. Blenman, K. R., B. Duan, Z. Xu, S. Wan, M. A. Atkinson, T. R. Flotte, B.P. Croker, and L. More. 2006. IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest. 86: 113611-113648.
54. Schroder, K., and J. Tschopp. 2010. The inflammasomes. Cell. 140: 821-822.
55. Shaw, P. J., M. F. McDermott, and T. D. Kanneganti. 2011. Inflammasomes and autoimmunity. Trends Mol Med. 17: 57-64.
56. Pontillo, A., M. Girardelli, A. J. Kamada, J. A. Pancotto, E. A. Donadi, S. Crovella, and P. Sandrin-Garcia. 2012. Polymorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 45: 271-278.
57. Bauernfeind, F. G., G. Horvath, A. Stutz, E. S. Alnemri, K. MacDonald, D. Speert, T. Fernandes-Alnemri, et al. 2009. Cutting Edge: NF-B activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 183: 787-791.
58. Shah, D., A. Wanchu, and A. Bhatnagar. 2011. Interaction between oxidative stress and chemokines: Possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology 216: 1010-1017.
59. Venegas-Pont, M., M. B. Manigrasso, S. C. Grifoni, B. B. LaMarca, C. Maric, L. C. Racusen, R. H. Glover, et al. 2010. Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension 56: 643-649.
60. Shah, D., R. Kiran, A. Wanchu, and A. Bhatnagar. 2010. Oxidative stress in systemic lupus erythematosus: Relationship to Th1 cytokine and disease activity. Immunol Lett. 129: 7-12.
61. Sarvestani, S. T., B. R. G. Williams, and M. P. Gantier. 2012). Human Toll-like receptor 8 can be cool too: Implications for foreign RNA sensing. J Interferon Cytokine Res. 32: 350-361.
62. Lin, Y. T., A. Verma, and C. P. Hodgkinson. 2012. Toll-like receptors and human disease: lessons from single nucleotide polymorphisms. Curr Genomics. 13: 633-645.
63. Yildirim-Toruner, C. and B. Diamond. 2011. Current and novel therapeutics in treatment of SLE. J Allergy Clin Immunol. 127: 303-314.